Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.41 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18725417 | 0.87 | NOTUM (0.47) | NOTUMMPODRD2DRD4DRD3 | |
| SCHEMBL17439979 | 0.83 | CHRM1 (0.50) | NOTUMMPODRD2DRD4DRD3 | |
| SCHEMBL18725445 | 0.81 | MPO (0.43) | NOTUMMPODRD2DRD4DRD3 | |
| SCHEMBL18725522 | 0.81 | NOTUM (0.41) | NOTUMMPODRD2DRD4DRD3 | |
| SCHEMBL17440053 | 0.80 | CHRM1 (0.51) | NOTUMMAPTCHRM1RORC | |
| SCHEMBL15775944 | 0.75 | CNR2 (0.47) | MPOMAPT | |
| SCHEMBL28050904 | 0.74 | NOTUM (0.49) | NOTUMMPODRD2DRD4DRD3 | |
| SCHEMBL17758747 | 0.73 | NOTUM (0.51) | NOTUMMPODRD2DRD4DRD3 | |
| SCHEMBL31366246 | 0.72 | NOTUM (0.61) | NOTUMDRD2DRD4DRD3KDM4E | |
| SCHEMBL27513112 | 0.72 | NOTUM (0.61) | NOTUMDRD2DRD4DRD3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | NOTUM 1908/4885MPO 765/4885DRD2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.